key: cord-1027541-6v5fa06e authors: Wan, Xiu‐Feng; Tang, Cynthia Y.; Ritter, Detlef; Wang, Yang; Li, Tao; Segovia, Karen; Kosikova, Martina; Johnson, Marc; Kwon, Hyung J.; Xie, Hang; Hammer, Richard D.; McElroy, Jane A.; Hamid, Aws; Collins, Natalie D.; Hang, Jun; Camp, Simone title: SARS‐CoV‐2 show no infectivity at later stages in a prolonged COVID‐19 patient despite positivity in RNA testing date: 2021-04-23 journal: J Med Virol DOI: 10.1002/jmv.27001 sha: 11b8c6746f0e0ab281122fed1714e2d6b74b2788 doc_id: 1027541 cord_uid: 6v5fa06e Inpatient coronavirus disease 2019 (COVID‐19) cases present enormous costs to patients and health systems in the United States. Many hospitalized patients may continue testing COVID‐19 positive even after the resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID‐19 over the course of a 2‐month hospitalization. Positive nasopharyngeal swab samples were collected and isolated in the laboratory and analyzed by quantitative reverse‐transcription polymerase chain reactions (qRT‐PCR), and serology was tested for neutralizing antibodies throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth by hospital day 41, suggesting no risk of infectivity, despite positive RT‐PCR results which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days after disease onset, which is longer than the discontinuation of transmission‐based precautions recommended by the Center for Disease Control and Prevention. Thus, our findings suggest that the timeline for discontinuing transmission‐based precautions may need to be extended for patients with severe and prolonged COVID‐19 disease. Additional large‐scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients. ​ Inpatient coronavirus disease 2019 (COVID-19) cases present enormous costs to patients and health systems in the United States. Many hospitalized patients may continue testing COVID-19 positive even after the resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID-19 over the course of a 2-month hospitalization. Positive nasopharyngeal swab samples were collected and isolated in the laboratory and analyzed by quantitative reverse-transcription polymerase chain reactions (qRT-PCR), and serology was tested for neutralizing antibodies throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth by hospital day 41, suggesting no risk of infectivity, despite positive RT-PCR results which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days after disease onset, which is longer than the discontinuation of transmission-based precautions recommended by the Center for Disease Control and Prevention. Thus, our findings suggest that the timeline for discontinuing transmission-based precautions may need to be extended for patients with severe and prolonged COVID-19 disease. Additional large-scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients. positive even after resolution of symptoms and infectivity, causing an extended hospitalization. [5] [6] [7] [8] In addition to measuring viral load, serological tests measuring antibody responses against SARS-CoV-2 are also valuable diagnostic tools. SARS-CoV-2-specific antibodies against the receptor binding domain (RBD), nucleocapsid (N), and spike (S) antigens vary over time, correspond to disease severity, and peak 1 to 2 months after symptom onset. 9 Neutralizing antibodies (Nabs), which function to bind to infectious viruses and minimize virus pathogenesis, have been shown to persist over 3 months, but can also rapidly decline within 2 months. 9,10 Thus, a pressing concern for clinicians is gauging the safety of discharging these asymptomatic patients: whether they have any remaining infectivity and whether they are adequately protected from additional infection. As of August 2020, the Center for Disease Control and Prevention (CDC) no longer recommends test-based strategies due to prolonged and detectable shedding in patients that no longer have infectivity. 11 The CDC recommends the following guidelines for the discontinuation of transmission-based precautions for persons with severe or critical illness: patients may be discontinued from transmission-based precautions up to 20 days after symptom onset, at least 24 h after the last fever, and improved symptoms. 11 In this case report, we present a patient with critical severity of COVID-19 disease who was still shedding infectious viruses at 24 days after symptom onset during his 2-month long hospitalization. This study was performed under the institutional review board (#2023844) and the Biosafety Level 3 (#20-14), in compliance with the Institutional Biosafety Committee of the University of Missouri-Columbia. The patient's clinical observations were documented at least twice daily and multiple nasopharyngeal swabs and plasma samples were collected and tested to determine viral loads and Nab titers. Periodic national early warning scores (NEWS) were assessed. A score of 7 or higher identifies high-risk patients requiring activation of a medical emergency team. 12 The patient's NEWS scores were between 8 and 12 from Day 33 through Day 45 and then remained below 7 from Day 46 until discharge. To test the viability of live virus in each of the viral samples at different time points of the patient's hospitalization, the viral samples were serially diluted from 1:10 1 to, at most, 1:10 12 in opti-minimal essential medium reduced-serum medium. Two hundred microliters of diluted virus were placed in four wells of Vero E6 cells that were seeded in 96-well plates for each dilution for 1 day and incubated at 37°C in 5% CO 2 for 3 days. Cytopathic effects were recorded. TCID50 represents the viral loads causing a cytopathic effect in 50% of the wells as calculated by the Reed-Muench method. 13 Additional methods are available in the Supporting Information Viral RNA was undetectable on D51 and inconclusive on D52. An inconclusive PCR result indicated that one of the controls from the PCR test was unsuccessful. Thus, an additional nasopharyngeal swab performed the following day (D53) and was positive again. A follow-up nasopharyngeal swab was collected and was still positive on D57 with markedly increased viral RNA load ( Figure 1C ). On D61 and D62, two nasopharyngeal swabs revealed undetectable viral RNA. The patient was discharged on D63 in stable condition. Due to the positive then negative then positive COVID-19 test results of this patient, the viruses were recovered and sequenced using one-step RT-PCR amplification with an integrated microfluidic system and next-generation sequencing 14 Growth assays for these three samples were performed to test for infectious virus, and only Sample 1at D17 (24 days after symptom onset) was viable. The viruses from all three samples belong to the GH lineage of SARS-CoV-2 ( Figure 1D ) with D614G in the S protein, P4715L in nonstructural protein (nsp) 12, T265I at nsp2, and Q57H at Comparison of neutralizing antibodies using microneutralization assays with live SARS-CoV-2 virus, neutralization analyses with pseudovirus expressing spike proteins, and ELISA assays Day NI-live GMT ( ± SD) NI-pseduo (mean tters) ELISA (mean titers) RBD S (full length) S1 S2 IgG IgM IgA IgG IgM IgA IgG IgM IgA IgG IgM IgA 29 403 (±1.49) 8600 8100 300 900 8100 300 900 8100 100 300 24,300 300 open reading frame 3a (ORF3a), consistent with the prevalent D614G/Q57H/T265I subclade in the United States. 15 A limited number of polymorphisms were identified among these three viruses ( Figure 1C ). Of note, A4771V at ORF1ab was identified only in Sample 2 but not in Samples 1 and 3. Plasma samples were collected between D29 and D57 for neutralization/inhibition (NI) and enzyme-linked immunosorbent assay (ELISA) determination ( Figure 1A , Table 1 ). Live SARS-CoV-2-based NI assays showed highly positive and constant Nab titers, ranging from 1:403 to 1:320, until D41. On D52, when the patient retested indeterminate then positive, the Nab geometric mean titer increased to 1:1016, remaining elevated until discharge. Pseudotyped NI results also indicated raised Nab titers on D52. ELISA results showed elevated RBD, S, S1, and S2-specific IgM, IgG, and IgA titers for the first 45 days (Table 1) . While other antibodies remained stable or began declining following the first negative test, RBD-specific IgG and S1-specific IgA titers continued rising throughout the hospitalization (Table 1) . Elevated RBD-specific IgG and S1-specific IgA titers correlated with the patient retesting positive on D52. In current CDC interim guidance on duration of isolation and pre- The primary limitation of this study is that the available data encompasses a single patient. Confounding factors include the multiple pharmaceutical treatments in addition to fluid maintenance and pain control (Table S1) that the patient received. Bacterial pneumonia was treated with broad spectrum antibiotics from D3-42. Antifungals were given to treat oral candidiasis D45-56, and methylprednisolone (steroid) was administered from D45 to D56 for eosinophilic bronchiolitis. In summary, the patient was on steroid medication and had just completed antifungal therapy when they retested positive for SARS-CoV-2 between D54 and D56. In summary, this report follows the clinical and serological timeline of a patient with severe and persistent COVID-19. This patient demonstrated viable virus growth at least 24 days after symptom onset. These findings suggest that separate discontinuation of transmission-based precaution guidelines for patients with persistent symptoms and extended hospital stays may be necessary. Virological analyses: Yang Wang Genomic sequencing: Tao Li Radiology: Aws Hamid. REFERENCES 1. World Health Organization. Coronavirus Disease (COVID-19) Dashboard; 2021 Average cost of hospital care for COVID-19 ranges from $51,000 to $78,000, based on age Covid-19: medical expenses leave many Americans deep in debt Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples Persistent positivity of SARS-CoV-2 nucleic acid in asymptomatic healthcare worker: infective virion or inactive nucleic acid? Longitudinal profiling of antibody response in patients with COVID-19 in a tertiary care hospital in Beijing, China. Frontiers in Immunology Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings National Early Warning Score (NEWS) 2 A simple method of estimating fifty percent endpoints Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon Variant analysis of SARS-CoV-2 genomes SARS-CoV-2: the viral shedding vs infectivity dilemma How to cite this article -2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing The authors declare that there are no conflict of interests. Manuscript draft: Xiu-Feng Wan, Cynthia Y. Tang, and Detlef Ritter. ORCID Cynthia Y. Tang http://orcid.org/0000-0001-5272-7170